Type1Cure tracks research, trials, devices, safety alerts, company movement, and community signals, then turns them into evidence-labeled briefings a parent can act on.
This desk is generated from the Type1Cure syndication feed, with official/public source pulls normalized into evidence-labeled items before they hit the page.
39 items from 4 live sources. Updated Jun 11, 2026, 2:15 PM CDT. Sources with temporary failures stay visible in feed health instead of silently disappearing.
RECRUITING. Interventions: Biosampling. Locations: Bobigny, Île-de-France Region, France | Bondy, Île-de-France Region, France | Colombes, Île-de-France Region, France. National multi-center non-interventional case-control cohort study with collection of biological samples to characterize the autoimmune T and B lymphocytes involved in the development of type 1 diabetes.
A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EG... Action: On 04/14/2026, the firm sent via the iOS App an "URGENT: MEDICAL DEVICE CORRECTION NOTIFICATION" communication informing custome...
A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EG... Action: On 04/14/2026, the firm sent via the iOS App an "URGENT: MEDICAL DEVICE CORRECTION NOTIFICATION" communication informing custome...
A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the foreground, causing the Glucose Compass to flicker through previous EG... Action: On 04/14/2026, the firm sent via the iOS App an "URGENT: MEDICAL DEVICE CORRECTION NOTIFICATION" communication informing custome...
Kits contain the McKesson TRUE Metrix PRO Professional Monitoring Blood Glucose System that has been recalled for an issue with the software design of the E-5 Error Code where the meter displays an E-5 error code for a very high blood glucose event (> 600 mg/dL) or when there is a test strip error, which can lead to operator confusion when evaluating patients and a delay in ap... Action: On 3/27/2026, correction notices were emailed to customers asking them to take the following actions: For Health Care Profession...
Due to a manufacturing defect, certain Omnipod 5 Pods from 49 lots have an internal soft cannula tear that results in insulin leaking into the Pod instead of being delivered to the user regardless of basal or bolus delivery. This defect results from damage to the unexposed portion of the soft cannula during manufacturing, which would result in a compromised fluid path. The pri... Action: Insulet notified consignees via press release and letters sent via email primarily and also text message on 03/12/2026. The pres...
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur whe... Action: On 2/13/2026, communications began via email, SMS, certified postal mail, and in-app push notifications. Correction notices were...
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur whe... Action: On 2/13/2026, communications began via email, SMS, certified postal mail, and in-app push notifications. Correction notices were...
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur whe... Action: On 2/13/2026, communications began via email, SMS, certified postal mail, and in-app push notifications. Correction notices were...
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur whe... Action: On 2/13/2026, communications began via email, SMS, certified postal mail, and in-app push notifications. Correction notices were...
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur whe... Action: On 2/13/2026, communications began via email, SMS, certified postal mail, and in-app push notifications. Correction notices were...
RECRUITING, PHASE1, PHASE2. Interventions: CELZ-201 Administration, Control Group. Locations: Miami, Florida, United States. The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
These are source-linked posts generated from the current Type1Cure feed: daily briefings, device safety watches, trial roundups, research watches, and editorial explainers.
A daily Type1Cure briefing built from current official and public source pulls, with each item labeled by source, evidence class, and family relevance.
A focused safety brief from the current FDA device recall lane, prioritizing CGM, pump, insulin-delivery, glucose-monitoring, and related diabetes-device records.
A plain-English watchlist of current recruiting Type 1 diabetes studies surfaced from ClinicalTrials.gov, with consent-first guardrails for families.
A daily research brief that separates literature discovery from clinical meaning, so promising headlines do not get mistaken for proven care changes.
Clinical trials, biotech filings, peer-reviewed papers
The highest-value watchlist combines islet or stem-cell derived beta cells, encapsulation, immune modulation, and durable insulin independence endpoints.
FDA, device makers, ADA technology updates
Closed-loop systems, CGM accuracy, interoperability, algorithm updates, infusion-set reliability, and recall notices deserve daily monitoring.
ClinicalTrials.gov, TrialNet, academic centers
Recruiting trials can be filtered by age, geography, disease stage, intervention class, and travel burden without storing sensitive profiles by default.
YouTube, creator feeds, podcasts, community submissions
Creator posts can surface practical lived experience and early buzz, but must be separated from clinical claims and sponsor influence.
A live PubMed query for T1D cure-watch, beta-cell, immunotherapy, stem-cell, islet, and technology terms. Preprints stay labeled separately until peer review.
ClinicalTrials.gov recruiting studies for Type 1 diabetes, used for NCT tracking, eligibility watch, intervention class, and location filters.
TrialNet is the first stop for family risk screening, prevention studies, and early-stage disease-modifying research pathways.
Breakthrough T1D organizes current clinical trial education, disease-modifying therapy trials, cell therapy trials, and virtual trial options.
The highest-priority safety lane for CGM, pump, sensor, infusion, app, blood-glucose monitor, and connected-device notices.
The clinical guideline anchor for diabetes care, technology, screening, hypoglycemia, school planning, and clinician-facing recommendations.
A stable government-backed patient education reference for Type 1 diabetes basics, symptoms, diagnosis, insulin, and family education.
A patient-community lens for daily-life topics, advocacy, family experience, practical gear, and stories that need evidence overlay.
Cure news has to be handled carefully. The product ranks items by evidence class, patient relevance, novelty, and actionability, then sends high-risk claims through human review.
View trust controlsEvery item is marked as peer reviewed, preprint, clinical trial, regulatory, company PR, news, social, or anecdotal.
No miracle language, no supplement hype, no diagnosis advice, and no pay-to-rank editorial placement.
Source pulls use retries, source checksums, canonical IDs, and duplicate protection before publication.
High-impact items, safety alerts, trial eligibility, and sponsor-sensitive content enter an editorial queue.
The source registry is treated as a product surface: every feed needs a method, cadence, trust tier, license/terms note, failure behavior, and a reason it matters to families.
DOI/NCT dedupe, phase tagging, human-vs-animal labeling, and plain-English evidence summaries.
Age, location, recruiting status, intervention class, endpoint, and contact changes tracked over time.
CGM, pump, infusion, insulin, glucagon, app, and interoperability alerts are escalated above news.
Company claims are labeled as PR until independently supported by clinical or regulatory evidence.
Official APIs, embeds, creator permission, and community submissions keep platform use compliant.
Commercial movement is separated from medical recommendations and ranked by patient relevance.
If FDA, MedWatch, or a manufacturer issues a relevant CGM, pump, app, insulin, or glucagon alert, it should bypass the normal feed and hit the family alert lane first.
FDA
Primary safety page for serious recalls and early alerts; this lane should always outrank news.
Open alertFDA / Insulet
Example of the kind of fast device issue that belongs in immediate family alerts.
Open alertFDA / Trividia Health
Blood-glucose monitoring alerts should be tagged by product, lot/model, action required, and severity.
Open alertFDA / Abbott Diabetes Care
CGM notices need a plain-language impact summary and a link to the manufacturer check/replacement path.
Open alertYouTube, podcasts, creator posts, parent forums, and lived experience can reveal what matters in real life. The site captures that signal while labeling anecdote, sponsorship, and platform limits clearly.
The first social release should use YouTube API, podcast RSS, manual creator watchlists, embeds where permitted, and community submissions. TikTok, Instagram, and Facebook require official APIs, permissions, or paid listening partners.
The revenue plan is designed to fund serious monitoring without letting advertisers, affiliates, or trial sponsors distort coverage.
Parents, advocates, clinicians, investors
Free weekly digest plus paid daily alerts, trial watches, and research briefs.
Editorial coverage never depends on payment from companies being covered.
Device, education, insurance navigation, nonprofit, and event partners
Clearly labeled newsletter, webinar, and event sponsorships.
Sponsors get reach, not editorial control, claims review, or hidden native ads.
Families buying practical T1D gear
Disclosed affiliate links for bags, patches, travel gear, books, and low supplies.
No affiliate influence on safety coverage, rankings, or medical claims.
Families looking for legitimate study opportunities
Privacy-minimal alerts and optional concierge matching.
No sale of health profiles; users control what is stored and shared.
Families need current opportunities, but the site should never imply eligibility or treatment fit. These links open the live trial sources while Type1Cure layers plain-English filters and consent-first alerts.
ClinicalTrials.gov recruiting studies for Type 1 diabetes, used for NCT tracking, eligibility watch, intervention class, and location filters.
Open recruiting trialsTrialNet is the first stop for family risk screening, prevention studies, and early-stage disease-modifying research pathways.
Open TrialNetBreakthrough T1D organizes current clinical trial education, disease-modifying therapy trials, cell therapy trials, and virtual trial options.
Open trial finder